Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

SOLIDARITY (interferon), 2020
 
NCT04315948
RCTinterferoncontrolCOVID 19 hospitalizedsome concern
2063/2064 inconclusive 14% 4%
Synairgen SG016, 2020
 
NCT04385095
RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedhigh
50/51 suggested 197% 119% -56%

COVID 19 all comers meta-analysis

Cai -FAVIPIRAVIR, 2020
 
ChiCTR2000029600
NRainterferonlopinavir/ritonavirCOVID 19 all comersNA
35/45 suggested 493%
Cai -FAVIPIRAVIR, 2020
 
ChiCTR2000029600
NRainterferoninterferonCOVID 19 all comersNA
35/45 suggested 493%

COVID-19 mild to moderate meta-analysis

Fu, 2020
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 no results
Idelsis, 2020
 
RPCEC00000307
RCTinterferoninterferonCOVID-19 mild to moderatehigh
30/33 conclusif
Khamis, 2020 RCTinterferonstandard of careCOVID-19 mild to moderatesome concern
44/45 inconclusive -15%

COVID-19 severe or critically meta-analysis

Davoudi-Monfared, 2020
 
IRCT20100228003449N2
RCTinterferonstandard of careCOVID-19 severe or criticallyhigh
46/46 no results
Yekaninejad, 2020
 
IRCT20100228003449N2
RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
33/33 conclusif

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).